Next Phase Newsletter

An early-stage venture capital firm based in Taipei, Taiwan, specializes in incubation, seed and early venture investments in technology-heavy sectors. The firm is currently investing from its $40 million fund that is set to close in 2016. Typical equity allocations range from $500K to $3M in seed to series A rounds. The firm generally leads a financing round but is also open to syndication. The firm is currently seeking opportunities from Taiwan and the United States.

Within life sciences, the firm considers medical devices, IVD tools, healthcare internet of things (IoT), and pharmaceuticals. Within medtech, the firm is looking for early stage projects that have significant entry barrier and can address unmet medical need. On-market products are less of interest. The firm is open to all risk levels and all disease indications. The firm is also interested in material science and agricultural biotech.

The firm is an active investor. The firm can work with incomplete teams, assist companies with regulatory strategy and product definition, and help overseas businesses find manufacturing partners in Taiwan. The firm typically takes a board seat in a portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private equity firm with a fund size of $150 million is interested in growth and buyout investments into middle market companies located in India. The firm’s typical investment size is $5m – $10m in exchange for 35%+ equity ownership. The firm is open to leading the round or co-investing alongside other firms.

The firm is interested a wide range of healthcare related sectors – including equipment, devices, biotech, suppliers and engineering, distributors, providers and payers. The firm will not invest in orphan diseases but is opportunistic with regard to indication areas. The firm has a broad range of interests but will invest only in companies based in India generating revenues of $5m – $15m.

The firm for strong, experienced and passionate management teams when making a minority investment. Management team requirements are less stringent if it is a buyout. The firm always takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private firm based in London, UK has an exclusive focus on healthcare. The firm seeks to invest £10M-£20M over the life of an investment, but initial investment can range from £1M-£5M. Investments are most commonly in the form of equity, although there is flexibility in regards to capital structure. The firm looks to make 2-3 investments per year in revenue-generating companies.

Within the healthcare space the firm is sector and indication agnostic, but intends to focus on medical products and healthcare services that aim to improve or reduce the cost of care provision, including health IT, digital health and software, primary and acute care models, homecare and social care, chronic disease management, dentistry, cosmetic and aesthetics but also medical equipment, specialty pharma, imaging, CROs and diagnostics.

There are no formal pre-requisites for company’s or management teams in terms of level of experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Shanghai-based merchant bank has a newly formed office in Cambridge, MA, that sources healthcare investment opportunities for China-based institutional investors. The firm is interested in both acquisitions and minority equity investments; allocations have varied from $30M to $1.5BN, but for healthcare deals the firm prefers to invest $75 million or more in a given opportunity. The firm seeks opportunities in North America and Europe.

The firm is interested in any opportunity in healthcare, but has a particular interest and expertise in medical device opportunities and healthcare service facilities. In the medical device sector, the firm is only interested in companies that have a revenue-generating product, but do not need to be profitable at this time. The firm is interested in all types of medical devices, and has expertise in orthopedics.

The firm’s primary criteria is a strong strategic fit with the firm’s China-based investors, who are seeking to bring the branding and medical expertise of North American or European medical technology companies to the Asia market. The firm is interested, but not exclusively seeking companies that are planning to expand into Asia, or to grow their existing Asia business. The firm is open to investing in companies that have revenues but not profits.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An evergreen fund is focused on seed to later-stage companies building infrastructure and value chains around big data, including but not limited to health and life science data. Typical investment sizes range from $250K – $1M for early-stage companies. Additional capital for follow-on investments is available for portfolio companies. Along with capital, the firm also provides access to their Asian network for later-stage companies needing market expansion (once all other aspects of the company’s business have been resolved). There is not a requirement for a board seat along with investments. The fund is focused on U.S. companies (with a focus on Silicon Valley), but will consider companies globally.

The firm invests in companies that are creating solutions to close the data feedback loop, including capturing data, analytics and instruments/robotics. The firm is interested in medical devices, diagnostics and healthcare IT products, with addressable markets of at least $1B. In the diagnostics field, m-health devices and genomics are of particular interest. The firm is open to all sub-sectors of health IT including consumer-facing hardware/software, data collection/management and data analytics. The firm will invest in medical devices and diagnostics that require FDA approval, with 510K regulatory pathway being the most common, although devices/services that require different regulatory pathways will also be considered. Companies developing hardware or robotics that automate scientific life science experiments are also of interest. The firm does not make any investments in therapeutics.

There are no formal requirements for management teams, but management teams with experience commercializing products are preferred.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A cross-border venture capital firm has offices in Northeastern US and Japan. The firm invests in early-stage therapeutic companies worldwide, with a focus on opportunities in North America. The firm may allocate up to $15 million per opportunity, but the amount initially committed varies dependent on the company’s stage of development, from under $1 million to $3-5 million for companies raising funds for IND-enabling studies.

The firm only invest in therapeutics, and are primarily focused on companies with preclinical assets. Within therapeutics, both small molecule and biologic opportunities are of interest. The firm may invest up to 18 months prior to IND, but require that a company has a lead asset that has been characterized, and has obtained proof of concept animal data that shows how the drug’s mechanism of action is playing out in the animal model. The firm also prefers that a company has additional follow-on drug candidates. In addition to preclinical opportunities, the firm also very selectively invests in companies with clinical-stage programs, but only in cases where the firm can add significant strategic value. The firm will consider opportunities in any indication area.

The firm invests in teams with experienced, highly motivated teams with a strong background in either life science research or industry. The firm only invests in companies with technology that has the potential to be first in class.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A multinational computer giant aims to build a community of organizations who share a vision for shaping the future of their industry through the power of cognitive computing. The firm has set up a $100m equity investment fund with a mission to invest in strategic partnerships that exhibit the firm’s capabilities across industries. The firm makes business-led investment based on the application of firm’s core technology. The firm seeks minority participation in venture-led, Series A-C rounds and typically avoids seed stage investment. The firm is currently reviewing new opportunities from North America and Europe.

The firm empowers development of applications utilizing its core technology. Within healthcare, the firm is seeking B2B/B2B2C solutions in clinical care, home care, health management, biopharmaceutical R&D, and veterinary fields. Startups are selected based on business and technical synergy to become its partners, who will obtain access to its cloud service and enter strategic co-development partnership with the firm.

The firm is looking for top talent and industry expertise to accelerate awareness of cognitive applications. The firm does not require a board seat in its investee companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com